Pharmacologic Stress Agent For Coronary Artery Disease Assessment Therapeutics
1. Lexiscan patent expiration
Treatment: Method of myocardial imaging; Method for stimulating coronary vasodilation for purposes of imaging the heart; A method of myocardial perfusion imaging and increasing coronary blood flow; Method of pro...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47351 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US8106183 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(1 year, 24 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8536150 | ASTELLAS | Methods of myocardial perfusion imaging |
Jun, 2019
(6 years ago) | |
| US8470801 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(6 years ago) | |
| US8106029 | ASTELLAS | Use of A2A adenosine receptor agonists |
Jun, 2019
(6 years ago) | |
| US7655637 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US7683037 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(6 years ago) | |
| US7655636 | ASTELLAS | Use of A2A adenosine receptor agonists |
Jun, 2019
(6 years ago) | |
| US7582617 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(6 years ago) | |
| US9289446 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(6 years ago) | |
| US7144872 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US6642210 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US9085601 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(1 year, 24 days from now) | |
| US9045519 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US8183226 | ASTELLAS | Myocardial perfusion imaging method |
Jun, 2019
(6 years ago) | |
| US7183264 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(6 years ago) | |
| US6403567 | ASTELLAS | N-pyrazole A2A adenosine receptor agonists |
Apr, 2022
(3 years ago) | |
| US8133879 | ASTELLAS | Myocardial perfusion imaging methods and compositions |
Jun, 2019
(6 years ago) | |
| USRE47301 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(1 year, 24 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2013 |
| M(M-194) | Jan 17, 2020 |
Drugs and Companies using REGADENOSON ingredient
NCE-1 date: 10 April, 2012
Market Authorisation Date: 10 April, 2008
Dosage: SOLUTION
How can I launch a generic of LEXISCAN before it's drug patent expiration?
More Information on Dosage
LEXISCAN family patents
